Alvotech (ALVO), Kashiv Biosciences, and Advanz Pharma said Wednesday that the UK Medicines and Healthcare Products Regulatory Agency has accepted the marketing application for AVT23, a proposed biosimilar to Xolair.
Xolair is indicated for the treatment of severe persistent allergic asthma and chronic rhinosinusitis, the companies said.
Alvotech and Advanz Pharma have a commercialization agreement for AVT23, while Alvotech and Kashiv have a licensing agreement for AVT23, according to the statement.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。